Asthma, Allergic Completed Phase 4 Trials for Omalizumab (DB00043)

Also known as: Asthma Atopic / Atopic Asthma / Allergic Asthma / Extrinsic asthma - atopy (& pollen) / Extrinsic asthma NOS (disorder) / Extrinsic asthma (disorder) / Allergic asthma (disorder) / Asthma extrinsic / Extrinsic asthma / Allergic atopic asthma [Ambiguous] / Asthma / Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever] / Extrinsic asthma [Ambiguous] (disorder) / Bronchial asthma / Other and unspecified asthma / Asthma, unspecified / Asthma bronchial / Asthma unspecified (disorder) / Asthmatic bronchitis NOS / Asthma: [NOS] or [attack] / Asthma NOS / (Asthma: [exercise induced] or [allergic NEC] or [NOS]) or (allergic bronchitis NEC) / Asthma (disorder) / Asthma NOS (disorder) / Asthmatic bronchitis (disorder) / Asthma (disorder) [Ambiguous] / Asthmatic / Br. asthma / Bronchitic asthma

IndicationStatusPhase
DBCOND0047182 (Asthma, Allergic)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00267202Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic AsthmaTreatment
NCT00283504A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE TherapyDiagnostic
NCT00670930Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonistsTreatment
NCT01125748A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term TherapyTreatment
NCT02023151Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in BasophilsTreatment